Compare · DFFN vs NVO
DFFN vs NVO
Side-by-side comparison of Diffusion Pharmaceuticals Inc. (DFFN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFFN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 7444.2x DFFN ($24.6M).
- NVO has hit the wire 8 times in the past 4 weeks while DFFN has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for DFFN).
- Company
- Diffusion Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $6.60+66.46%
- $41.01-4.51%
- Market cap
- $24.6M
- $183.15B
- 1M return
- -
- -10.44%
- 1Y return
- -
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DFFN
- SEC Form SC 13G/A filed by Diffusion Pharmaceuticals Inc. (Amendment)
- SEC Form 4 filed by Boger Joshua S
- SEC Form SC 13D filed by Diffusion Pharmaceuticals Inc.
- New insider Boger Joshua S claimed ownership of 561,309 shares (SEC Form 3)
- Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Diffusion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Alam John J
- SEC Form 4 filed by Blackburn Kelly
- SEC Form 4 filed by Tanner John William
- SEC Form 4 filed by Elder William Robert
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care